Literature DB >> 25691096

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Shane Stegeman1, Ernest Amankwah2, Kerenaftali Klein3, Tracy A O'Mara4, Donghwa Kim5, Hui-Yi Lin6, Jennifer Permuth-Wey2, Thomas A Sellers2, Srilakshmi Srinivasan1, Rosalind Eeles7, Doug Easton8, Zsofia Kote-Jarai9, Ali Amin Al Olama8, Sara Benlloch8, Kenneth Muir10, Graham G Giles11, Fredrik Wiklund12, Henrik Gronberg12, Christopher A Haiman13, Johanna Schleutker14, Børge G Nordestgaard15, Ruth C Travis16, David Neal17, Paul Pharoah18, Kay-Tee Khaw19, Janet L Stanford20, William J Blot21, Stephen Thibodeau22, Christiane Maier23, Adam S Kibel24, Cezary Cybulski25, Lisa Cannon-Albright26, Hermann Brenner27, Radka Kaneva28, Manuel R Teixeira29, Amanda B Spurdle4, Judith A Clements1, Jong Y Park2, Jyotsna Batra30.   

Abstract

UNLABELLED: Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role. SIGNIFICANCE: Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25691096      PMCID: PMC4390388          DOI: 10.1158/2159-8290.CD-14-1057

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  50 in total

1.  Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.

Authors:  R Stege; M Grande; K Carlström; B Tribukait; A Pousette
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  Thermodynamics of RNA-RNA binding.

Authors:  Ulrike Mückstein; Hakim Tafer; Jörg Hackermüller; Stephan H Bernhart; Peter F Stadler; Ivo L Hofacker
Journal:  Bioinformatics       Date:  2006-01-29       Impact factor: 6.937

3.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap.

Authors:  Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker
Journal:  Bioinformatics       Date:  2008-10-30       Impact factor: 6.937

4.  Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene.

Authors:  Helena Persson; Anders Kvist; Natalia Rego; Johan Staaf; Johan Vallon-Christersson; Lena Luts; Niklas Loman; Goran Jonsson; Hugo Naya; Mattias Hoglund; Ake Borg; Carlos Rovira
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

5.  MicroRNA binding site polymorphisms as biomarkers of cancer risk.

Authors:  Cory Pelletier; Joanne B Weidhaas
Journal:  Expert Rev Mol Diagn       Date:  2010-09       Impact factor: 5.225

6.  Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.

Authors:  A H Fortier; J W Holaday; H Liang; C Dey; D K Grella; J Holland-Linn; H Vu; S M Plum; B J Nelson
Journal:  Prostate       Date:  2003-08-01       Impact factor: 4.104

7.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.

Authors:  Mitchell G Lawrence; John Lai; Judith A Clements
Journal:  Endocr Rev       Date:  2010-01-26       Impact factor: 19.871

8.  Enhanced energy expenditure, glucose utilization, and insulin sensitivity in VAMP8 null mice.

Authors:  Haihong Zong; Cheng-Chun Wang; Bhavapriya Vaitheesvaran; Irwin J Kurland; Wanjin Hong; Jeffrey E Pessin
Journal:  Diabetes       Date:  2010-09-28       Impact factor: 9.461

9.  Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.

Authors:  Junying Chen; Desheng Yao; Yue Li; Hong Chen; Chanjuan He; Nan Ding; Yan Lu; Tingyu Ou; Shan Zhao; Li Li; Fengyi Long
Journal:  Int J Mol Med       Date:  2013-06-21       Impact factor: 4.101

10.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.

Authors:  Danielle Welter; Jacqueline MacArthur; Joannella Morales; Tony Burdett; Peggy Hall; Heather Junkins; Alan Klemm; Paul Flicek; Teri Manolio; Lucia Hindorff; Helen Parkinson
Journal:  Nucleic Acids Res       Date:  2013-12-06       Impact factor: 16.971

View more
  24 in total

1.  Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.

Authors:  Nevena Kotarac; Zorana Dobrijevic; Suzana Matijasevic; Dusanka Savic-Pavicevic; Goran Brajuskovic
Journal:  Pathol Oncol Res       Date:  2020-06-17       Impact factor: 3.201

2.  Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.

Authors:  Srilakshmi Srinivasan; Carson Stephens; Emily Wilson; Janaththani Panchadsaram; Kerry DeVoss; Hannu Koistinen; Ulf-Håkan Stenman; Mark N Brook; Ashley M Buckle; Robert J Klein; Hans Lilja; Judith Clements; Jyotsna Batra
Journal:  Clin Chem       Date:  2018-12-11       Impact factor: 8.327

3.  New functions assigned to a microRNA with genetic links to prostate cancer risk.

Authors:  Akira Kurozumi; Shawn E Lupold
Journal:  Ann Transl Med       Date:  2019-09

4.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

5.  A Single Nucleotide Polymorphism in HPGD Gene Is Associated with Prostate Cancer Risk.

Authors:  Xiaofei Qi; Yu Wang; Jianquan Hou; Yuhua Huang
Journal:  J Cancer       Date:  2017-10-24       Impact factor: 4.207

Review 6.  Genomic Insight into the Role of lncRNA in Cancer Susceptibility.

Authors:  Ping Gao; Gong-Hong Wei
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

7.  Profile of common prostate cancer risk variants in an unscreened Romanian population.

Authors:  Paul D Iordache; Dana Mates; Bjarni Gunnarsson; Hannes P Eggertsson; Patrick Sulem; Júlíus Guðmundsson; Stefania Benónísdóttir; Irma Eva Csiki; Stefan Rascu; Daniel Radavoi; Radu Ursu; Catalin Staicu; Violeta Calota; Angelica Voinoiu; Mariana Jinga; Gabriel Rosoga; Razvan Danau; Sorin Cristian Sima; Daniel Badescu; Nicoleta Suciu; Viorica Radoi; Andrei Manolescu; Thorunn Rafnar; Bjarni V Halldórsson; Viorel Jinga; Kári Stefánsson
Journal:  J Cell Mol Med       Date:  2017-12-20       Impact factor: 5.310

8.  Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.

Authors:  Bongyong Lee; Jian-Liang Li; John Marchica; Mark Mercola; Vipul Patel; Ranjan J Perera
Journal:  J Hum Genet       Date:  2021-06-08       Impact factor: 3.172

9.  Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.

Authors:  Alessio Naccarati; Fabio Rosa; Veronika Vymetalkova; Elisa Barone; Katerina Jiraskova; Cornelia Di Gaetano; Jan Novotny; Miroslav Levy; Ludmila Vodickova; Federica Gemignani; Tomas Buchler; Stefano Landi; Pavel Vodicka; Barbara Pardini
Journal:  Oncotarget       Date:  2016-04-26

10.  Ganoderma lucidum polysaccharide inhibits prostate cancer cell migration via the protein arginine methyltransferase 6 signaling pathway.

Authors:  Xiaohui Zhao; Dayu Zhou; Yunen Liu; Chun Li; Xiaoguang Zhao; Ying Li; Wei Li
Journal:  Mol Med Rep       Date:  2017-10-26       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.